Rhenman & Partners Asset Management’s Evolent Health EVH Stock Holding History

Rhenman & Partners Asset Management’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-265,000	Closed	-$7.49M	–	96
2024 Q3	$7.49M	Buy	265,000 +215,000	+430%	+$5.54M	0.61%	53
2024 Q2	$956K	Buy	+50,000	New	+$1.28M	0.09%	91
2024 Q1	–	Sell	-230,000	Closed	-$7.6M	–	86
2023 Q4	$7.6M	Buy	230,000 +85,000	+59%	+$2.41M	0.76%	46
2023 Q3	$3.95M	Hold	145,000	–	–	0.43%	60
2023 Q2	$4.39M	Buy	+145,000	New	+$4.69M	0.46%	59

Other funds holding EVH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Rhenman & Partners Asset Management's EVH Position: Q4 2024 in Review

Rhenman & Partners Asset Management sold out of Evolent Health (EVH) in Q4 2024, closing a stake of 265,000 shares — an estimated $7.49M sold.

Rhenman & Partners Asset Management first reported a position in EVH in Q2 2023 and held it in 5 quarters. The position peaked at $7.6M in Q4 2023. 240 funds tracked by Wall St. Rank hold EVH as of Q4 2024.

Rhenman & Partners Asset Management reported no remaining Evolent Health position as of Q4 2024 after selling out during the quarter.
Rhenman & Partners Asset Management sold 265,000 Evolent Health shares in Q4 2024, an estimated $7.49M.
Rhenman & Partners Asset Management first reported a position in Evolent Health in Q2 2023 and held it in 5 quarters.
Rhenman & Partners Asset Management's Evolent Health position peaked at $7.6M in Q4 2023.
240 funds tracked by Wall St. Rank held Evolent Health as of Q4 2024.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2024, filed 13 Feb 2025.